Royalty Pharma plc and Revolution Medicines, Inc. have announced a strategic funding collaboration of up to $2 billion to support the global development and commercialization ...
Continue reading
In a significant development, the European Patent Office (EPO) has revoked Salix Pharmaceuticals’ European patent for the antibiotic rifaximin. In decision T 0162/22, the ...
Continue reading
We are happy to report that we successfully defended Merck’s formulation patent EP 3 996 688 for c-Met inhibitor Tepotinib (TEPMETKO®) in opposition proceedings at the hea...
Continue reading
For more awards and information, click here.
